Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cariprazine dose-reduction relapse prevention in schizophrenia
NCT03593213Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2018
- Primary completion
- Feb 2021
- Modality
- Orthosteric Ligands
- Countries
- 11
01
Overview
A Phase 3 trial of cariprazine in schizophrenia, sponsored by AbbVie Inc.. Started Jul 2018; status: terminated.
02
Drugs
cariprazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03593213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03593213.